Diplomat discusses role of patient advocacy on Pharmacy Podcast
FLINT, Mich. — Diplomat on Wednesday released its second episode in partnership with Pharmacy Podcast. The new installment discusses the role of patient advocacy within the specialty pharmacy field. Diplomat’s manager of patient advocacy, Brenda Hawkes, joins Pharmacy Podcast’s Todd Eury for this conversation.
“Patient advocacy means complete and thorough support of our patients throughout the nation,” Hawkes said. “The goal is to reach out to the advocacy groups and patient support groups that work with the patients who take the medications we fill prescriptions for.”
One notable component of Diplomat’s patient advocacy is outreach at patient support group meetings and conferences. Hawkes and other members of Diplomat’s staff work with patients, caregivers and advocates, regardless of whether or not they utilize Diplomat’s services, to provide information about the various resources for patient assistance that are available to them.
In addition to external efforts, Hawkes is also part of a team inside the company that works to coordinate staff education programs. Diplomat staff members have regular opportunities to learn more about what it is like to live with a serious disease or condition. The added education leads to improved care.
“I’ve always been impressed, [Diplomat is] such a large organization but they haven’t forgot their roots,” stated Eury, “and the patient advocacy is at the heart of it all.”
Deal complete, McKesson owns more than 75% of Celesio
SAN FRANCISCO — McKesson on Thursday confirmed that it has completed the previously announced agreement with Franz Haniel & Cie. GmbH to acquire their entire holding of Celesio shares. McKesson also confirmed it has completed the previously announced agreement with an affiliate of Elliott Management to acquire Celesio convertible bonds.
McKesson now exceeds 75% ownership of Celesio shares on a fully diluted basis.
The deal places McKesson on par with its competitors in terms of generic sourcing. The McKesson-Celesio deal is expected to generate a combined generic purchasing power of between $9.5 billion and $11.5 billion, according to an analysis by FBR Capital Markets. A similar analysis of the respective purchasing power of CVS Caremark and Cardinal Health has their combined purchasing power coming in between $9.5 billion and $11.5 billion. According to FBR, the Walgreens-Amerisource-Bergen-ABC Consortium has about $12 billion in combined generic purchasing power.
Sandoz launches generic Hectorol
PRINCETON, N.J. — Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol. Doxercalciferol injection vials are used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” Peter Goldschmidt, President of Sandoz, said.
The company will market the drug in 4 mcg/2 mL single-dose vials.